1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

US filing for Avastin in first-line ovarian cancer 'unlikely' despite European nod

 
• By Sukaina Virji

The European Commission has approved Avastin (bevacizumab) from Roche in combination with chemotherapy for front-line advanced ovarian cancer, but Roche says that there is a "low likelihood" of a US filing in the first-line setting.

The European Commission has approved Avastin (bevacizumab) from Roche in combination with chemotherapy for front-line advanced ovarian cancer, but Roche says that there is a "low likelihood" of a US filing in the first-line setting.

Avastin's approval in HER2-negative metastatic breast cancer was revoked in the US (and Canada) recently, a decision at odds with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 
• By Jessica Merrill

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By Mandy Jackson

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.